Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 5/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847277 | 0.81 | ALDH1A1 (0.35) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL5847814 | 0.81 | ALDH1A1 (0.34) | ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL7476649 | 0.79 | HDAC6 (0.46) | KDM4E | |
| SCHEMBL6241333 | 0.77 | ALOX15 (0.39) | ALDH1A1MAPTKDM4ERAB9A | |
| SCHEMBL6247685 | 0.77 | ALOX5 (0.45) | ALDH1A1MAPT | |
| SCHEMBL7114643 | 0.77 | OGG1 (0.47) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL6240951 | 0.75 | L3MBTL1 (0.46) | ALDH1A1KDM4EPOLBGAA | |
| SCHEMBL5848690 | 0.74 | LMNA (0.36) | ALDH1A1NPC1RAB9AGAA | |
| SCHEMBL5847923 | 0.74 | LMNA (0.39) | ALDH1A1NPC1RAB9AGAA | |
| SCHEMBL5847286 | 0.74 | GAA (0.44) | ALDH1A1MAPTKDM4EPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015223-B1 | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | claimed |
| US-7015230-B1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | claimed |
| US-20050165021-A1 | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-07-28 | — | — | US | claimed |
| US-20050153965-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-07-14 | — | — | US | claimed |
| US-6908919-B2 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-06-21 | — | — | US | claimed |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | claimed |
| EP-1268463-B1 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORP (US) | 2005-02-16 | — | — | EP | claimed |
| US-6852761-B2 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-02-08 | — | — | US | claimed |
| US-20040171839-A1 | Polycyclic aryl and heteroaryl substituted 1, 4-quinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-09-02 | — | — | US | claimed |
| US-20040171616-A9 | Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-09-02 | — | — | US | claimed |
| US-20020025947-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2002-02-28 | — | — | US | claimed |
| US-20020022604-A1 | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | PHAMACIA CORPORATION | 2002-02-21 | — | — | US | claimed |
| US-20020010344-A1 | Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2002-01-24 | — | — | US | claimed |
| WO-2001087854-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | claimed |
| WO-2001087851-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIMIDINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | claimed |
| WO-2001087852-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | claimed |
| WO-2001079155-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 1,4-QUINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| WO-2001077097-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001077079-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001068605-A1 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED BENZENES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165021-A1 | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, F2 | ALDH1A1 3342/4885MAPT 3800/4885KDM4E 1107/4885 |
| US-20050153965-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | TFPI, F2, PLAT | ALDH1A1 2284/4885MAPT 4843/4885KDM4E 2122/4885 |
| US-20040171839-A1 | Polycyclic aryl and heteroaryl substituted 1, 4-quinones useful for selective inhibition of the coagulation cascade | TFPI, SERPINC1, F2 | ALDH1A1 938/4885MAPT 4416/4885KDM4E 1525/4885 |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | ALDH1A1 3516/4885MAPT 4321/4885KDM4E 2800/4885 |
| US-20020010344-A1 | Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade | TFPI, SERPINC1, F2 | ALDH1A1 938/4885MAPT 4416/4885KDM4E 1525/4885 |
| US-20040171616-A9 | Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade | TFPI, SERPINC1, F2 | ALDH1A1 938/4885MAPT 4416/4885KDM4E 1525/4885 |
| US-20020025947-A1 | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | ALDH1A1 2669/4885MAPT 4263/4885KDM4E 2446/4885 |
| US-20020022604-A1 | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, F2 | ALDH1A1 3342/4885MAPT 3800/4885KDM4E 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.